BE534066A - - Google Patents

Info

Publication number
BE534066A
BE534066A BE534066DA BE534066A BE 534066 A BE534066 A BE 534066A BE 534066D A BE534066D A BE 534066DA BE 534066 A BE534066 A BE 534066A
Authority
BE
Belgium
Prior art keywords
emi
transformation
process according
aminoketones
acetylene
Prior art date
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Publication of BE534066A publication Critical patent/BE534066A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/48Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

       

  Le procédé qui fait l'objet de l'invention sert à fabriquer des oxyacétylènes contenant des groupes amino, de grande valeur thérapeutique

  
et qui présentent des avantages particuliers surtout en tant que sédatifs pratiquement inoffensifs, aussi bien au point de vue de leur administration

  
 <EMI ID=1.1> 

  
en médecine sous l'appellation de narcylène, exerce un effet narcotique.

  
Cet effet du groupe éthinyle a trouvé aussi applications dans quelques médicaments que l'on rencontre dans le commerce comme calmants respec-

  
 <EMI ID=2.1> 

  
pour ces usages sont toutefois en partie liquides et doivent donc être administrées sous forme de liquide ou en capsules de gélatine, ou bien encore elles doivent être transformées en combinaisons susceptibles de donner des comprimés. Dans certains cas, elles se caractérisent par une forte odeur

  
qui gêne de nombreux malades et elles présentent en outre une pression de vapeur élevée qui peut occassionner certaine gêne chez le patient qui les

  
a avalées. Dans les essais sur animaux, il s'est avéré que, lors de l'administration de moyens connus à base de groupe éthinyle, un stade d'excitation plus ou moins prononcé et non désiré précédait en général l'état de sommeil.

  
Selon le procédé qui fait l'objet de l'invention, on fabrique

  
des oxyacétylènes et dérivés, porteurs de groupes amino, par transformation d'aminocétones avec de l'acétylène ou des dérivés d'acétylène, de préférence en présence de moyens de condensation à effet basique, comme par exemple le sodium, l'amide de sodium, les hydroxydes alcalins ou de terres alcalines ou les hydrures alcalins ou de terres alcalines et on obtient des produits qui ne présentent pas les inconvénients susmentionnés. Au moyen

  
du procédé qui fait l'objet de l'invention, on arrive en général à des substances solides cristallisant bien qui, soit comme telles soit certainement sous la forme de leur sel, permettent aisément la préparation de comprimés

  
et qui, comme l'ont montré les essais sur animaux, produisent sans stade d'excitation préalable un état somnolent au cours duquel l'animal entend encore. Des nouveaux sédatifs sont pratiquement inoffensifs car la dose,

  
 <EMI ID=3.1> 

  
que pour la plupart des préparations connues contenant des groupes d'éthinyle. Grâce à l'azote basique contenu dans les produits, il se forme immédiatement, sous l'influence de l'acide gastrique, un chlorhydrate qui, de plus, peut être administré comme tel et avec le même effet. Etant donné

  
que les chlorhydrates ne possèdent pratiquement plus de pression de vapeur, il n'y a pas ici de gêne provoquée par l'odeur. En outre, la plupart de

  
ces sels sont facilement solubles dans l'eau, ce qui assure une résorption homogène. 

  
 <EMI ID=4.1> 

  
mation entre aminocétones avec de l'acétylène. Parmi les aminocétones entrant en ligne de compte se sont avérés particulièrement bons, au point de vue allure de la transformation-, qualité des produits et facilité de la formation de sel, les aminocétones fortement basiques, surtout ceux avec de l'azote combiné tertiairement, comme il le sera montré dans un exemple, on peut toutefois partir aussi de pyridylcétones et obtenir ainsi des combinaisons qui peuvent être employées comme agents sédatifs.

  
Selon une variante du procédé qui fait l'objet de l'invention,

  
les éthinylaminoalcools sont transformés en sels correspondants avec des acides organiques ou inorganiques, comme indiqué déjà ci-avant à l'exemple

  
 <EMI ID=5.1> 

  
acide hydrobromique ou de l'acide bro&#65533;valérianique qui renforcent encore

  
 <EMI ID=6.1> 

  
dant ou par transformation en éther-oxyde. 

  
Le procédé qui fait l'objet de l'invention convient pour la transformation d'aminocétones de toute sorte et peut s'appliquer aussi en employant des aminocétones qui contiennent, par groupe amino, un à trois groupes céto. On peut l'appliquer aussi avec succès à des amino-dicétones et amino-tricétones mais il y aura avantage à choisir les matières de départ telles qu'il

  
y ait par groupe céto un groupe amino substitué ou non substitué.

  
 <EMI ID=7.1> 

  
invention pour obtention du l-isopropyle-4-éthinyle-piperidol-4 agissant comme sédatif et de grande valeur au point de vue pharmacologique.

  
EXEMPLE 1.-

  
 <EMI ID=8.1> 

  
On chauffe alors légèrement, petit à petit, en remuant. On produit alors

  
la combinaison avec un gazomètre à acétylène et, en secouant, l'acétylène est absorbé par le mélange de réaction. Quand la quantité nécessaire d'acétylène est absorbée,le produit de réaction est décomposé avec de l'eau froide et-un peu de glace et la base éthinyle formée est absorbée dans du benzol. La solution benzolique est séchée au sulfate de soude, le solvant est éliminé par distillation puis distillé par vide .hydraulique. A 12-13 mm., le l-isopropyle-4-éthinyle-piperidol-4 formé passe en rendement presque quan-

  
 <EMI ID=9.1> 

  
La formule est la suivante:

  
1-1 sopropyle-4-éthinyle-piperidol-4

  

 <EMI ID=10.1> 


  
 <EMI ID=11.1> 

  
On peut, de fagon analogue, obtenir les combinaisons suivantes qui présentent des effets thérapeutiques tout à fait identiques:

  
hors de diméthylamino acétone et acétylène

  
 <EMI ID=12.1> 

  

 <EMI ID=13.1> 


  
La formule est la suivante:

  
2-Diméthylamino-méthyle-butinol-2

  

 <EMI ID=14.1> 


  
EXEMPLE 3.

  
 <EMI ID=15.1> 
 <EMI ID=16.1> 
  <EMI ID=17.1> 

  

 <EMI ID=18.1> 


  
De ce produit on peut fabriquer par transformation en éther-oxyde, par exem-

  
 <EMI ID=19.1> 

  

 <EMI ID=20.1> 


  
La formule est la suivante:

  
 <EMI ID=21.1> 

  

 <EMI ID=22.1> 


  
Au lieu de l'éther-oxyde susindiqué, on peut aussi employer avec succès un

  
 <EMI ID=23.1> 

  

 <EMI ID=24.1> 


  
 <EMI ID=25.1> 

  

 <EMI ID=26.1> 


  
 <EMI ID=27.1> 

  

 <EMI ID=28.1> 


  
La formule est la suivante:

  
 <EMI ID=29.1> 

  

 <EMI ID=30.1> 


  
Les combinaisons prénommées peuvent encore être changées, sans que soit affectée leur efficacité, en remplaçant le groupe méthyle par un groupe éthyle ou propyle. 

  
 <EMI ID=31.1> 

  

 <EMI ID=32.1> 


  
 <EMI ID=33.1> 

  

 <EMI ID=34.1> 


  
 <EMI ID=35.1> 

  

 <EMI ID=36.1> 


  
 <EMI ID=37.1> 
 <EMI ID=38.1> 
 EXEMPLE 8.-

  
hors de diméthylaminoacétone et phénylacétylène

  
 <EMI ID=39.1> 

  

 <EMI ID=40.1> 


  
EXEMPLE 9.

  
 <EMI ID=41.1> 

  

 <EMI ID=42.1> 


  
 <EMI ID=43.1> 

  
butin-1-3- 13 - pyridyl-3-ol

  

 <EMI ID=44.1> 


  
Les produits obtenus, abstraction faite de ceux de 1* exemple 10, peuvent être reproduits par les formules suivantes;

  

 <EMI ID=45.1> 


  
 <EMI ID=46.1>   <EMI ID=47.1> 

  

 <EMI ID=48.1> 


  
 <EMI ID=49.1> 

  
R7 signifie méthyle; il y a lieu de revendiquer toutefois, de façon générale, un reste d'alcoyle avec jusque 3 atomes de carbone

  
 <EMI ID=50.1> 
- égal à 1 à 4.

REVENDICATIONS.

  
 <EMI ID=51.1> 

  
lènes, de préférence en présence de moyens de condensation basiques, des aminocétones, en particulier ceux dont les groupes amino peuvent former avec des acides forts, par exemple l'acide chlorhydrique, des sels réagissant neutralement en solution.



  The process which is the object of the invention serves to manufacture oxyacetylenes containing amino groups, of great therapeutic value.

  
and which present particular advantages especially as practically harmless sedatives, both from the point of view of their administration

  
 <EMI ID = 1.1>

  
in medicine under the name of narcylene, exerts a narcotic effect.

  
This effect of the ethinyl group has also found applications in some drugs which are found in commerce as respective sedatives.

  
 <EMI ID = 2.1>

  
for these uses are however partly liquid and must therefore be administered in liquid form or in gelatin capsules, or else they must be converted into combinations capable of producing tablets. In some cases, they are characterized by a strong odor

  
which bothers many patients and they also present a high vapor pressure which can cause some discomfort in the patient who

  
swallowed. In animal tests, it has been found that, when administering known means based on an ethinyl group, a more or less pronounced and unwanted stage of excitement generally precedes the state of sleep.

  
According to the process which is the subject of the invention,

  
oxyacetylenes and derivatives, carrying amino groups, by transformation of aminoketones with acetylene or acetylene derivatives, preferably in the presence of condensation means with a basic effect, such as for example sodium, sodium amide , alkali metal or alkaline earth hydroxides or alkali metal or alkaline earth hydrides, and products are obtained which do not exhibit the aforementioned drawbacks. Thanks to

  
of the process which is the subject of the invention, one generally arrives at solid substances which crystallize well which, either as such or certainly in the form of their salt, easily allow the preparation of tablets

  
and which, as animal tests have shown, produce without a previous stage of excitement a drowsy state in which the animal can still hear. New sedatives are practically harmless because the dose,

  
 <EMI ID = 3.1>

  
than most of the known preparations containing ethinyl groups. Thanks to the basic nitrogen contained in the products, under the influence of gastric acid, a hydrochloride is immediately formed which, moreover, can be administered as such and with the same effect. Given

  
since the hydrochlorides hardly have any more vapor pressure, there is no discomfort caused by the odor here. In addition, most of

  
these salts are easily soluble in water, which ensures homogeneous absorption.

  
 <EMI ID = 4.1>

  
mation between aminoketones with acetylene. Among the aminoketones taken into account have been shown to be particularly good from the point of view of processing rate, product quality and ease of salt formation, strongly basic aminoketones, especially those with tertiary combined nitrogen, as will be shown in one example, however, it is also possible to start from pyridyl ketones and thus obtain combinations which can be employed as sedative agents.

  
According to a variant of the method which is the subject of the invention,

  
the ethinylaminoalcohols are converted into corresponding salts with organic or inorganic acids, as already indicated above in the example

  
 <EMI ID = 5.1>

  
hydrobromic acid or bro valerianic acid which further strengthen

  
 <EMI ID = 6.1>

  
dant or by transformation into an ether oxide.

  
The process which is the subject of the invention is suitable for the transformation of aminoketones of all kinds and can also be applied by employing aminoketones which contain, per amino group, one to three keto groups. It can also be applied successfully to amino diketones and amino triketones, but it will be advantageous to choose starting materials such as

  
by keto group is a substituted or unsubstituted amino group.

  
 <EMI ID = 7.1>

  
invention for obtaining 1-isopropyl-4-ethinyl-piperidol-4 which acts as a sedative and of great pharmacological value.

  
EXAMPLE 1.-

  
 <EMI ID = 8.1>

  
Then heat slightly, little by little, while stirring. We then produce

  
the combination with an acetylene gasometer and, with shaking, the acetylene is absorbed by the reaction mixture. When the necessary amount of acetylene is absorbed, the reaction product is decomposed with cold water and a little ice and the ethinyl base formed is absorbed in benzol. The benzolic solution is dried with sodium sulphate, the solvent is removed by distillation and then distilled by hydraulic vacuum. At 12-13 mm., The 1-isopropyl-4-ethinyl-piperidol-4 formed passes in yield almost as much.

  
 <EMI ID = 9.1>

  
The formula is as follows:

  
1-1 sopropyl-4-ethinyl-piperidol-4

  

 <EMI ID = 10.1>


  
 <EMI ID = 11.1>

  
In a similar way, the following combinations can be obtained which exhibit completely identical therapeutic effects:

  
out of dimethylamino acetone and acetylene

  
 <EMI ID = 12.1>

  

 <EMI ID = 13.1>


  
The formula is as follows:

  
2-Dimethylamino-methyl-butinol-2

  

 <EMI ID = 14.1>


  
EXAMPLE 3.

  
 <EMI ID = 15.1>
 <EMI ID = 16.1>
  <EMI ID = 17.1>

  

 <EMI ID = 18.1>


  
From this product can be produced by transformation into ether-oxide, for example

  
 <EMI ID = 19.1>

  

 <EMI ID = 20.1>


  
The formula is as follows:

  
 <EMI ID = 21.1>

  

 <EMI ID = 22.1>


  
Instead of the above-mentioned ether-oxide, one can also successfully use a

  
 <EMI ID = 23.1>

  

 <EMI ID = 24.1>


  
 <EMI ID = 25.1>

  

 <EMI ID = 26.1>


  
 <EMI ID = 27.1>

  

 <EMI ID = 28.1>


  
The formula is as follows:

  
 <EMI ID = 29.1>

  

 <EMI ID = 30.1>


  
The above-named combinations can still be changed, without affecting their effectiveness, by replacing the methyl group with an ethyl or propyl group.

  
 <EMI ID = 31.1>

  

 <EMI ID = 32.1>


  
 <EMI ID = 33.1>

  

 <EMI ID = 34.1>


  
 <EMI ID = 35.1>

  

 <EMI ID = 36.1>


  
 <EMI ID = 37.1>
 <EMI ID = 38.1>
 EXAMPLE 8.-

  
excluding dimethylaminoacetone and phenylacetylene

  
 <EMI ID = 39.1>

  

 <EMI ID = 40.1>


  
EXAMPLE 9.

  
 <EMI ID = 41.1>

  

 <EMI ID = 42.1>


  
 <EMI ID = 43.1>

  
booty-1-3- 13 - pyridyl-3-ol

  

 <EMI ID = 44.1>


  
The products obtained, apart from those of Example 10, can be reproduced by the following formulas;

  

 <EMI ID = 45.1>


  
 <EMI ID = 46.1> <EMI ID = 47.1>

  

 <EMI ID = 48.1>


  
 <EMI ID = 49.1>

  
R7 signifies methyl; in general, however, an alkyl residue with up to 3 carbon atoms should be claimed

  
 <EMI ID = 50.1>
- equal to 1 to 4.

CLAIMS.

  
 <EMI ID = 51.1>

  
lenes, preferably in the presence of basic condensation means, aminoketones, in particular those whose amino groups can form with strong acids, for example hydrochloric acid, salts which react neutrally in solution.


    

Claims (1)

2) Procédé suivant la revendication 1, caractérisé par le fait qu'on emploie des aminopétones avec atome d'azote tertiairement combiné. 2) Process according to claim 1, characterized in that aminopetones with tertiary combined nitrogen atom are used. 3) Procédé suivant les revendications 1 et 2, caractérisé par le fait que les oxyacétylènes produits sont transformés en sels avec des acides organiques ou inorganiques et qu'on emploie de préférence à cet effet des acides qui exercent une influence sédative. 3) Process according to claims 1 and 2, characterized in that the oxyacetylenes produced are converted into salts with organic or inorganic acids and that acids which exert a sedative influence are preferably used for this purpose. 4) Procédé suivant les revendications 1 à 3, caractérisé par le fait que les groupes OH libres des oxyacétylènes sont bloqués par éthérification ou transformation en éther-oxyde, par exemple par transformation en ester valérianique ou carbamique. 4) Process according to claims 1 to 3, characterized in that the free OH groups of the oxyacetylenes are blocked by etherification or transformation into ether-oxide, for example by transformation into valerian or carbamic ester.
BE534066D 1953-12-24 BE534066A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE1161319X 1953-12-24

Publications (1)

Publication Number Publication Date
BE534066A true BE534066A (en)

Family

ID=7728447

Family Applications (1)

Application Number Title Priority Date Filing Date
BE534066D BE534066A (en) 1953-12-24

Country Status (2)

Country Link
BE (1) BE534066A (en)
FR (1) FR1161319A (en)

Also Published As

Publication number Publication date
FR1161319A (en) 1958-08-26

Similar Documents

Publication Publication Date Title
EP0233106B1 (en) (-)-benzhydrylsulfinylacetamide, process for its preparation and its use in therapy
CA2102778C (en) Novel compositions based on taxane class derivatives
CA1203242A (en) 3-hydroxybutanoic acid salt derivatives and of an amino organic base, and salts therefrom
EP0671912A1 (en) Injectable taxane derivative based compositions
CH629479A5 (en) TAURIN DERIVATIVES, MEDICAMENT CONTAINING THESE DERIVATIVES AND PROCESS FOR PREPARING THESE DERIVATIVES.
FR2914188A1 (en) Pharmaceutical composition, useful as medicine, preferably as drugs in the treatment of degenerative diseases, comprises oxime based chloestenone compounds or their esters or derivatives, and oil or its mixture
EP0068998B1 (en) (z)-1-aryl-2-aminomethyl-cyclopropane-carboxylates, their preparation and their use as medicines in the treatment of various disorders
FR2584405A1 (en) FUROSEMIDE SALTS, PHARMACEUTICAL COMPOSITION CONTAINING THEM AND PROCESS FOR THEIR PREPARATION
BE534066A (en)
FR2505834A1 (en) DERIVATIVES OF THIAZOLIDINE
FR2559771A1 (en) DERIVATIVES OF 3-PYRROLIDINOPROPOPHENONE AND PROCESS FOR THEIR PREPARATION
EP0113330A1 (en) Acylated enamide compounds, pharmaceutical compositions containing them and use of these compounds
EP0108017A1 (en) Mixture comprising a central analgesic and vitamin B12, or one of its analogs, as active principles
BE1003959A5 (en) Therapeutic agent for treatment of disorders associated with cerebral ischemia.
FR1759M (en)
CA1095067A (en) Hydrocarbyl-thio-ethylamies salts and their applications
BE646581A (en)
CA2028326A1 (en) Furosemide salts, process for the preparation thereof, application as medicaments and pharmaceutical compositions containing them
BE897217A (en) NEW ANTI-INFLAMMATORY, ANALGESIC AND ANTIPYRETIC DRUG BASED ON (P-CHLOROBENZOYL-1, METHYL- 2- Methoxy-5) Indole-3 P-Acetamidophenol Acetate
BE620468A (en)
CH646182A5 (en) DERIVATIVE OF 5-PREGNAN-20-OL AND ITS SALTS WITH ACIDS, THEIR PREPARATION AND THE MEDICINAL PRODUCTS CONTAINING THEM.
FR2516795A1 (en) MEDICAMENT FOR THE TREATMENT OF RESPIRATORY DISEASES COMPRISING A MEDICAMENT AGAINST RESPIRATORY DISEASES AND A HYDROXYCYCLOHEXYLAMINE OR ONE OF ITS SALTS
EP0264306A2 (en) 4-(2-Naphthyl methoxy) piperidine for the treatment of obesity
CH667809A5 (en) COMBINATION CONTAINING, AS ACTIVE INGREDIENTS, A CENTRAL ANALGESIC AND ADENINE.
BE724120A (en)